Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Raises $41M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Oxford Nanopore today said that it has raised £25 million ($41 million) in a private placement of ordinary shares.

The Oxford, UK-based nanopore sequencing firm said that it would use the funds to support further development, external validation, and production capabilities for its technology in DNA sequencing and protein analysis applications. The firm's platform technology, GridION, consists of a scalable, modular instrument and consumable cartridge.

Investors in the round included existing and new institutional and individual investors in the US and UK. Among the investors were Landsdowne Partners, IP Group, Invesco Perpetual, Redmile Group, and Illumina.

Illumina previously invested $18 million in Oxford Nanopore in early 2009 as part of a partnership to further develop and commercialize Oxford's DNA sequencing technology.

Oxford Nanopore also raised £17.4 million in a round of funding in early 2010. Previous to the private financing announced today, Oxford Nanopore had raised around £49 million since its inception in 2005.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.